Ketamine | Jotup

Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At American Society Of Clinical Psychopharmacology Annual Meeting

Retrieved on:

Dienstag, Mai 21, 2024

Randomness, Patient, Ketamine, Depression, FDA, Drug development, Tablet, Pharmacokinetics, Psychiatry, CNS, Comparison, Society, ASCP, Annual general meeting, Pharmaceutical industry

MUNICH, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma , announced today the Company will present poster presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place on May 28-31, 2024 at Miami Beach.

Key Points:

MUNICH, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma , announced today the Company will present poster presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place on May 28-31, 2024 at Miami Beach.
Dr. Hans Eriksson, Chief Medical Officer of Ketabon and HMNC Brain Health, will elucidate details on topline results of its Phase 2 trial with KET01, an oral ketamine treatment with minimal side effects, showing rapid improvements in depression severity and Ketabon’s comparative study between KET01 and intranasal SPRAVATO®, the current FDA-approved ketamine formulation.
Presentation details are as follows:
Poster: Comparison of Tolerability, Safety, and Pharmacokinetics of Antidepressant Doses of Oral Ketamine Prolonged Release Tablets (KET01) and Intranasal Esketamine: A Randomized, Placebo-Controlled, Double-Blind, Cross-Over Trial
“We are honored to speak at the premier CNS drug development gathering, where we'll be sharing KET01’s potential to significantly simplify treatment and provide an option for care beyond clinical settings, ensuring comfort and convenience for patients at home,” said Dr. Hans Eriksson, Chief Medical Officer of Ketabon and HMNC Brain Health.
“As a company committed to pioneering personalized therapies in psychiatry, we're deeply grateful for the opportunity to continue advancing alternative treatments for patients grappling with treatment-resistant depression.”
For more information on the Ketabon program, please visit https://www.ketabon.health/ .

Delix Announces DLX-001 Demonstrates Evidence of CNS Penetration and Brain Activity Without Psychotomimetic, Dissociative, or Hallucinogenic Effects in Ongoing Phase 1 Trial

Retrieved on:

Montag, Mai 13, 2024

The Company also announced preclinical data showing the effects of DLX-001 on antidepressant, structural, and functional plasticity assays.

Key Points:

The Company also announced preclinical data showing the effects of DLX-001 on antidepressant, structural, and functional plasticity assays.
Part B is an open-label crossover design study to investigate the effect of food on the PK of DLX-001.
No psychotomimetic, hallucinatory, or dissociative effects have been observed, as reflected by no change over time on a robust battery of assessments.
DLX-001 exhibited both rapid—within 24-hours, and enduring—up to 14 days, antidepressant-like activity after a single dose in multiple behavioral models.

Numinus Wellness Focused on Boosting Profitability and Expanding Community Support

Retrieved on:

Dienstag, Mai 7, 2024

Safety, Psychedelic drug, TSX, Research, Gold, Patient, Ketamine, Growth, Nursing

"We are excited to enter this next stage of our development, which sharpens our focus on expanding access to psychedelic-assisted therapies and accelerates our path to profitability.

Key Points:

"We are excited to enter this next stage of our development, which sharpens our focus on expanding access to psychedelic-assisted therapies and accelerates our path to profitability.
We aim to empower a broader community of drug developers and healthcare providers by optimizing our therapy, research, and training expertise.
They will also be part of the Numinus community with access to continuous learning, discounts on Numinus training and promotion of their professional profiles.
We look forward to continuing to support these services in Canada through our Numinus Network and the arrangement with Field Trip Health."

DEA Rescheduling of Cannabis A Big Win for Patients

Retrieved on:

Mittwoch, Mai 1, 2024

Tylenol, Codeine, CFP, Associated, News, Hope, NFL, Schedule, Testosterone, Entrepreneurship, Federation, Cannabis, Injury, Press, Patient, War, Schedule 3, DEA, Ketamine, Drug

WASHINGTON, April 30, 2024 /PRNewswire/ -- The Cannabis Freedom Party (CFP) is very pleased to learn of the news from the Associated Press that the U.S. Drug Enforcement Administration will move to reclassify cannabis as a Schedule 3 drug. The CFP sees this reclassification as a major win for the industry and patients.

Key Points:

The CFP sees this reclassification as a major win for the industry and patients.
While some may say that descheduling is truly what's needed, today's decision put necessary points on the board for medical cannabis patients across this country," said Ricky Williams, Co-Founder of CFP.
According to the DEA, Schedule III drugs, substances, or chemicals are defined as drugs with a moderate to low potential for physical and psychological dependence.
The rescheduling of cannabis to Schedule 3, this will now open the door for countless other patients who need access to this life saving medicine," said Jim McMahon, Co-Founder of CFP.

UT Health San Antonio-led STRONG STAR Consortium secures $17 million in DOD research funding for brain injuries, PTSD and more

Retrieved on:

Dienstag, April 30, 2024

SAN ANTONIO, April 29, 2024 /PRNewswire-PRWeb/ -- In a recent round of grant awards, the STRONG STAR Consortium based at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) was selected by the U.S. Department of Defense for a total of $17 million in funding to launch eight new research projects focused on traumatic brain injury and psychological health.

Key Points:

"Another is tinnitus, which is a persistent ringing in the ears that can develop after a brain injury.
Tinnitus is also commonly comorbid with PTSD, and it both contributes to and is impacted by psychological distress."
Some of these projects will be led by UT Health San Antonio investigators and others by STRONG STAR collaborators at other institutions, with research participants from a variety of military and VA study sites.
The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver of San Antonio's $44.1 billion health care and biosciences sector, is the largest academic research institution in South Texas with an annual research portfolio of $413 million.

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

Retrieved on:

Donnerstag, April 18, 2024

Pain, FDA, Hospital, Food, Health Canada, Depression, Quality, Suicidal ideation, Ketamine, Anesthesia, Mental health, Symantec Endpoint Protection, DSM-IV codes, CRL, Anxiety, Letter, Pharmaceutical industry

Ketamine has been on the FDA’s drug shortage list since February 2018, which is believed to have encouraged the widespread availability of compounded ketamine products not FDA approved for psychiatric disorders.

Key Points:

Ketamine has been on the FDA’s drug shortage list since February 2018, which is believed to have encouraged the widespread availability of compounded ketamine products not FDA approved for psychiatric disorders.
Ketamine is an essential medicine used for anesthesia and analgesia (pain relief) listed on the WHO Essential Medicines List .
In Canada, ketamine has been classified as a Tier 3 drug shortage since February 2023, and Health Canada has approved ketamine for use as a sedative and painkiller in hospital settings.
A recently published new peer-reviewed study on the real-world effectiveness of ketamine intravenous therapy demonstrated significant patient improvement for depression, anxiety and suicidal ideation.

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

Retrieved on:

Dienstag, April 16, 2024

Pain, FDA, Hospital, Food, Health Canada, Depression, Quality, Suicidal ideation, Ketamine, Anesthesia, Mental health, Symantec Endpoint Protection, DSM-IV codes, Anxiety, Pharmaceutical industry

TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its Priority Original Abbreviated New Drug Application (“ANDA”) for Ketamine that was accepted by the U.S. Food and Drug Administration (the “FDA”) and assigned a Generic Drug User Fee Amendments of 2022 (“GDUFA”) goal date of April 29, 2024.

Key Points:

TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its Priority Original Abbreviated New Drug Application (“ANDA”) for Ketamine that was accepted by the U.S. Food and Drug Administration (the “FDA”) and assigned a Generic Drug User Fee Amendments of 2022 (“GDUFA”) goal date of April 29, 2024.
The Company is prepared to address potential FDA requests and concerns immediately and will update shareholders as they occur.
Ketamine has been on the FDA’s drug shortage list since February 2018, which is believed to have encouraged the widespread availability of compounded ketamine products not FDA approved for psychiatric disorders.
A recently published new peer-reviewed study on the real-world effectiveness of ketamine intravenous therapy demonstrated significant patient improvement for depression, anxiety and suicidal ideation.

Relief Mental Health Sheds Light on Innovative Treatments During Mental Health Awareness Month

Retrieved on:

Mittwoch, Mai 1, 2024

As Mental Health Awareness Month kicks off today, Relief Mental Health aims to spotlight innovative therapies that offer hope to individuals struggling with mental health diagnoses.

Key Points:

As Mental Health Awareness Month kicks off today, Relief Mental Health aims to spotlight innovative therapies that offer hope to individuals struggling with mental health diagnoses.
"TMS, Spravato, and IV ketamine represent a new frontier in mental health treatment, offering relief to those who have struggled with traditional therapies,” said Teresa Poprawski, MD , a neuropsychiatrist and chief medical officer at Relief Mental Health.
In honor of Mental Health Month and to help educate the public on the benefits of TMS specifically, Relief Mental Health is hosting an Instagram Live event on Friday, May 17, at 10 a.m. central time.
For more information about Relief Mental Health or to schedule a consultation for any of its services, individuals can call 855.205.4764, email [email protected] or visit reliefmh.com .

First Annual U.S.-Ukraine Veterans' Charity Golf Tournament Announced with General Retired David Petraeus as Guest of Honor

Retrieved on:

Donnerstag, April 18, 2024

RET, The War, Guest, Veteran, Woman, Policy, PTSD, Research, Employment, David Petraeus, Ketamine, Commander, Thermography, Golf, Heroes, Multimedia, Rehabilitation, Organization, Naming, CIA

All proceeds from this golf tournament will go to the Borderlands Foundation whose mission is to "Make Sure Ukraine's Heroes are Never Forgotten."

Key Points:

All proceeds from this golf tournament will go to the Borderlands Foundation whose mission is to "Make Sure Ukraine's Heroes are Never Forgotten."
The day will conclude with the dinner Awards Gala that will feature General Petraeus' talk, a musical performance, and a fundraising raffle.
Sponsorship opportunities at this charity golf event offer significant visibility and networking benefits, with various levels available.
Visit U.S.-Ukraine Veterans' Charity Golf Tournament to secure participation in this historic event.

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

Retrieved on:

Montag, April 15, 2024

Pain, HOPE, Dark Enlightenment, Nephron, Ketamine, Therapy

This new formulation has the key advantage of achieving neutral pH, in contrast to the acidic pH of generic formulations of ketamine.

Key Points:

This new formulation has the key advantage of achieving neutral pH, in contrast to the acidic pH of generic formulations of ketamine.
Acidic substances are tolerated when diluted for intravenous use, but cause pain and may cause skin ulcers if administered subcutaneously.
NeuroRx, Inc. previously executed a joint development agreement with a manufacturer of insulin pumps but has been awaiting a suitable, pH neutral formulation of ketamine.
With this proprietary formulation, developed with our partner Nephron Pharmaceuticals, a leading sterile products manufacturer, NRx is expected to generate one or more patents, such as composition of matter or formulation.